At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 6 enrolled
Drug / intervention
OPCdrug
Likely dose
OPC 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites Following a Single Dose Oral Administration
In Brief
A Phase 1 clinical trial evaluating OPC for Parkinson's Disease (PD). Completed, enrolled 6 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the rate and routes of excretion of OPC and the mass balance in urine, faeces and expired air.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease (PD)
CountriesNetherlands
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2011
Primary CompletionJul 2011
First PostedJun 2014
TodayJul 2026
First PostedJun 23, 2014
Enrollment StartMar 1, 2011
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 12.0 years ago
Interventions
OPCdrug
The drug substance of 100 mg OPC was administered as 1 capsule.